Global Immunoglobulins Market Set to Surpass US$ 20 Bn by 2026, Concludes Fact.MR

According to the Immune Deficiency Foundation (IDF), approximately 83 per 100,000 people in North America suffered from primary immunodeficiency in 2017, covering 350 genetic diseases.
Spread the Word
Listed Under



Dublin 2 - Dublin - Ireland


DUBLIN 2, Ireland - May 20, 2020 - PRLog -- The global immunoglobulins market is set to grow impressively at a CAGR of 7.0% during the forecast period (2020-2026). The market is poised to reach a valuation of US$ 20.7 Bn by 2026-end. Upsurge in immunological diseases has prompted individuals to seek advanced medical treatment, thus augmenting the immunoglobulins market share.

The Immune Deficiency Foundation (IDF) estimates that approximately 83 people per 100,000 in North America suffer from primary immunodeficiency, leading to the prevalence of such diseases. In response, off-label indications, intravenous and subcutaneous immunoglobulins has risen considerably. Rising geriatric population pool shall also steer market growth. The ongoing COVID-19 pandemic is anticipated to provide leverage to the immunoglobulins market as healthcare providers are increasingly researching ways to apply immunoglobulins to treat the disease.

Key Takeaways of Global Immunoglobulins Market Study:

• By application, the neurology segment is forecast to hold a significant portion of the global immunoglobulins market (~2/5th). Rising prevalence of neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Multifocal Motor Neuropathy are anticipated to leverage the segment's growth.
• By administration route, the intravenous segment (IVIG) is anticipated to capture more than three-fourth of the global immunoglobulin market, expanding healthily at a CAGR of 7.0%. This is due to increased approval of products such as Carimune NF, Flebogamma DIF and GAMMAGARD S/D to treat major chronic rare diseases. Simultaneously, the subcutaneous segment is anticipated to expand healthily at a CAGR of 8.3% during the forecast period.
• With respect to end-use, the homecare segment is set to surpass all others during the forecast period. Better supervision of patients while undergoing infusions is a key driver behind the segment's expansion. The homecare segment is set to register a staggering CAGR of 8.3%, capturing almost two-fifths of the overall immunoglobulins market.
• North America is forecast to dominate the global immunoglobulins market across the forecast period. Rising prevalence of immunological and neurological disorders, adoption of IVIG products as well as significant reimbursement coverage shall leverage market share. The region shall account for nearly half of the global immunoglobulins market, expanding at a CAGR of 7.1%.
• Asia-Pacific is anticipated to grow the fastest, at a CAGR of 8.5% throughout the forecast period. Expanding healthcare markets, untapped potential, acceptance of immunoglobulins products in developing countries and increasing geriatric population are key drivers expected to leverage the region's growth prospects.

Read Report-

Email:*** Email Verified
Location:Dublin 2 - Dublin - Ireland
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fact.MR PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share